Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target

Herzog, Thomas

450 - Poster Session B
Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target

Sunday, March 23, 2014: 7:40 PM

West Exhibit Hall (Tampa Convention Center)

T. J. Herzog¹, K. Anderson², J. Wang² and R. Xu²
¹Columbia University & Herbert Irving Comprehensive Cancer Center, New York, NY, ²Merck & Co., Inc., Whitehouse Station, NJ

45th Annual Meeting on Women's Cancer

March 21 - 25, 2014

Navigation

450 - Poster Session B
Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target

450 - Poster Session B Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target

450 - Poster Session B
Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target